Transcriptomic Analysis of Type 2 Diabetes Mellitus Combined with Lower Extremity Atherosclerotic Occlusive Disease
Guang Zeng,Yong-Zhi Jin,Yi Huang,Jun-Sheng Hu,Meng-Fan Li,Ming Tian,Jun Lu,Rong Huang
DOI: https://doi.org/10.2147/dmso.s432698
2024-02-29
Diabetes Metabolic Syndrome and Obesity Targets and Therapy
Abstract:Guang Zeng, 1, &ast Yong-Zhi Jin, 1, &ast Yi Huang, 1 Jun-Sheng Hu, 1 Meng-Fan Li, 2 Ming Tian, 3 Jun Lu, 4 Rong Huang 1 1 Department of General Surgery, Putuo Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, 200062, People's Republic of China; 2 Department of General Surgery, LiQun Hospital, Shanghai, 200333, People's Republic of China; 3 Department of Burn, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, People's Republic of China; 4 Department of Endocrinology, Putuo Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, 200062, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jun Lu; Rong Huang, Email ; Background: The pathological damage mechanism of type 2 diabetes (T2D) and macroangiopathy is extremely complex, and T2D and arteriosclerosis obliterans have different biological behaviors and clinical features. To explore the mechanism of lower extremity arteriosclerosis occlusion (LEAOD) in T2D patients, we utilized RNA-seq to identify unique gene expression signatures of T2D and LEAOD through transcriptomic analysis. Methods: We obtained blood samples and performed RNA sequencing from four patients with T2D, five of whom had LEAOD. Another six age- and gender-matched blood samples from healthy volunteers were used for control. By exploring the general and specific differential expression analysis after transcriptome sequencing, specific gene expression patterns of T2D and LEAOD were verified. Results: Transcriptome analysis found differentially expressed genes in T2D, and T2D + LEAOD (vs normal) separately, of which 35/486 (T2D/T2D + LEAOD) were up-regulated and 1290/2970 (T2D/T2D + LEAOD) were down-regulated. A strong overlap of 571 genes across T2D, LEAOD, and coexisting conditions was mainly involved in extracellular exosomes and the transcription process. By exploring the sex difference gene expression features between T2D, T2D + LEAOD, and healthy controls, we noticed that sex chromosome-associated genes do not participate in the sexual dimorphism gene expression profiles of T2D and LEAOD. Protein–Protein Interaction Network analysis and drug target prediction provided the drug candidates to treat T2D and LEAOD. Conclusion: This study provides some evidence at the transcript level to uncover the association of T2D with LEAOD. The screened hub genes and predicted target drugs may be therapeutic targets. Keywords: type 2 diabetes mellitus, lower extremity arterial disease, gene expression profile, hub gene Diabetes mellitus is a disorder in which the pancreas cannot make enough insulin or respond normally to blood sugar (glucose), causing high blood sugar (hyperglycemia), and finally resulting in health problems, such as heart disease, nerve damage, and eye issues. 1 Type 2 diabetes (T2D) is the most common type of diabetes, representing 90% to 95% of all diabetes cases, and is characterized by elevated blood sugar caused by insulin secretion defect or insulin utilization disorder. 2,3 It is estimated that the number of diabetic patients worldwide will rise to 454 million by 2030 and 548 million by 2045. 4,5 T2D can cause a variety of complications, of which diabetic vascular disease is the most common. Diabetic vascular disease includes macrovascular disease and microvascular disease. Diabetic macrovascular disease refers to atherosclerosis of the aorta, coronary arteries, and peripheral arteries of the limbs. T2DM can cause microvascular and peripheral vascular lesions, leading to lower extremity atherosclerotic occlusive disease (LEASOD), limb ischemia and intermittent claudication, and even lower extremity ulcer, gangrene, or amputation in severe cases. 6 LEASOD is one of the most common peripheral arteriosclerosis occlusive diseases in current society, and it is an important part of systemic arteriosclerosis disease. Its pathological changes are a group of chronic ischemic diseases that cause arterial stenosis or occlusion, such as thickening of arterial intima, calcification, and secondary thrombosis. 7,8 The incidence of LEASOD is increasing year by year, and 70–80% of patients have no clinical symptoms. Some early manifestations, such as fatigue after exercise and soreness of the lower limbs, are often mistaken by people as a presentation of old age and/or fatigue. Some patients are insensitive to pain due to neuropathy caused by diabetes, and most patients have intermittent claudication, resting pain, ischemic gangrene, and other symptoms when it is difficult to treat, thus, se -Abstract Truncated-
endocrinology & metabolism